Authors
Yuto Mori, Keito Suto, Norio Takei, Keito Yokoyama, Masahiro Chiba, Takashi Ishio, Hideki Goto, Tomoyuki Endo, Hiroo Hasegawa, Michiyuki Maeda, Satoko Otsuguro, Katsumi Maenaka, Takanori Teshima, Yibin Yang, Masao Nakagawa
Published in
Leukemia. Jul 13, 2026. Epub Jul 13, 2026.
Abstract
Peripheral T-cell lymphomas (PTCLs) are aggressive malignancies with poor clinical outcomes and limited treatment options. Brentuximab vedotin (BV), a CD30-targeted antibody-drug conjugate, has shown efficacy in CD30-positive PTCLs but is frequently associated with incomplete responses and relapse. To enhance its therapeutic effect, we previously identified defects in spindle assembly checkpoint (SAC) regulation as key sensitizers to BV via a genome-wide CRISPR-Cas9 screen. Building on this, we conducted a cell cycle-focused chemical screen and identified polo-like kinase 1 (PLK1) inhibitors as potent synergistic partners for BV. Among them, volasertib consistently enhanced BV-induced cytotoxicity across multiple CD30-positive PTCL cell lines. Mechanistically, the BV-volasertib combination induced sustained mitotic arrest through activation of the SAC, followed by mitotic catastrophe, apoptosis, and DNA damage. This SAC dependence was further supported by the use of a selective Mps1 inhibitor. Importantly, the combination significantly suppressed tumor growth and prolonged survival in both cell line-derived and patient-derived xenograft (PDX) models. These findings underscore the therapeutic potential of combining BV with PLK1 inhibition, and highlight SAC activation as a key mechanism to overcome therapeutic resistance in CD30-positive PTCL.
PMID:
42443409
Bibliographic data and abstract were imported from PubMed on 14 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 2
- Comments 0